Search Filters:

The items contained in the list are being used to filter the search results. Click them to remove them from the search filter.
Displaying 61 - 80 of 241
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published Sort ascending
MHRA-101572-PIP01-24
  • Nogapendekin alfa
  • Inbakicept
  • Treatment of malignant bladder neoplasms
  • ANKTIVA
  • ANKTIVA
  • Uro-Nephrology
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101465-PIP01-24
  • anitocabtagene autoleucel
  • Treatment of multiple myeloma
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101547-PIP01-24
  • IgG-like T cell engager binding to DLL3 and CD3
  • Treatment of small cell lung carcinoma
  • Treatment of neuroendocrine carcinoma, (excluding neuroblastoma)
  • Not available at present
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101523-PIP01-24
  • Raludotatug deruxtecan
  • Treatment of Ovarian cancer
  • Treatment of fallopian tube cancer
  • Treatment of primary peritoneal cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101506-PIP01-24
  • Zongertinib
  • Treatment of non-small cell lung cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101442-PIP01-24
  • Modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens V940 (mRNA-4157)
  • Treatment of urothelial carcinoma
  • Treatment of cutaneous squamous cell carcinoma
  • Treatment of renal cell carcinoma
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101384-PIP01-24
  • Telisotuzumab adizutecan
  • Treatment of colorectal carcinoma.
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101500-PIP01-24
  • Zanidatamab
  • Treatment of gastroesophageal adenocarcinoma (GEA).
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101499-PIP01-24
  • Zanidatamab
  • Treatment of HER2-positive breast cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101426-PIP01-24
  • Deutetrabenazine
  • Treatment of tardive dyskinesia
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Neurology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101129-PIP01-23
  • Domvanalimab
  • Treatment of lung cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101128-PIP01-23
  • Domvanalimab
  • Treatment of gastric and gastroesophageal junction adenocarcinoma. Treatment of oesophageal carcinoma.
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101441-PIP01-24
  • modified recombinant version of the human myeloid-derived growth factor
  • Treatment of ischaemic coronary artery disorders
  • Not available at present
  • Cardiovascular Diseases
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101493-PIP01-24
  • anti-alpha-synuclein recombinant humanised monoclonal antibody (Company code UCB7853)
  • Treatment of Parkinson's disease
  • Neurology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101630-PIP01-24-M01 (update)
  • LISOCABTAGENE MARALEUCEL
  • Treatment of B-lymphoblastic leukaemia/lymphoma
  • Treatment of mature B-cell neoplasm
  • Breyanzi
  • Breyanzi
  • Breyanzi
  • Breyanzi
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101520-PIP01-24-M01 (update)
  • ECULIZUMAB
  • Treatment of neuromyelitis optica spectrum disorders.
  • SOLIRIS
  • SOLIRIS
  • Neurology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101496-PIP01-24
  • zirconium (89Zr) girentuximab senvedoxam
  • Diagnostic evaluation of indeterminate renal masses detected by conventional imaging
  • Not available at present
  • Uro-Nephrology
  • Diagnostic
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101395-PIP01-24
  • Zanidatamab
  • Treatment of biliary tract cancer (BTC).
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101410-PIP01-24
  • ISATUXIMAB
  • Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue
  • Sarclisa
  • Sarclisa
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101334-PIP01-24
  • Insulin Efsitora Alfa (LY3209590)
  • Treatment of type 1 diabetes mellitus
  • Treatment of type 2 diabetes mellitus
  • Endocrinology-Gynaecology-Fertility-metabolism
W: decision granting a waiver in all age groups for the listed condition(s). No